Market Overview

Saladax Biomedical Launches Game-Changing Assays for Psychotherapeutics at AACC 2018


Saladax is Advancing Personalized Medicine by Providing Psychiatrists
with the New MyCare Line of Assays to Improve Patient Treatment


  • MyCare Psychiatry™ line provides greater clarity on the causes of
    treatment failure and may help distinguish medication non-response
    from lack of adherence
  • First six assays are for the most commonly used antipsychotic
  • Reagents can run on automated clinical chemistry analyzers with
    open channels
  • Rapid turnaround time vs. LC-MS/MS

Saladax Biomedical Inc., a diagnostics company providing kits to test
drug blood levels for adherence and personalized dose management, will
announce at AACC the launch of a new line of tests for psychiatry in
Europe (CE mark).

"We engineered the MyCare Psychiatry line based on psychiatrists' needs
and extensive research of the market," said Dr. Salvatore J. Salamone,
Founder/CEO. "The result is a game-changer that delivers clinicians
access to rapid quantitative blood levels of the psychotherapeutic drugs
their patients are on. The MyCare line delivers a fast and accurate
result, giving physicians timely information of high medical value,
needed to better treat their patients."

The MyCare Psychiatry line will launch with tests for: clozapine,
quetiapine, aripiprazole, risperidone, olanzapine and paliperidone, five
of which are currently available for sale in Europe. The MyCare
Psychiatry™ panel of tests addresses a critical, unmet need for quickly
identifying levels of antipsychotic drugs in a patient's body. A
one-hour turnaround time is possible in a STAT mode within a laboratory.
Rapid testing has the potential to reduce treatment failures and to
positively impact patient management. Saladax announced, on July 17, the
submission of a De Novo classification request to the U.S. Food and Drug
Administration (FDA) for the MyCare Psychiatry™ Total Risperidone Assay
Kit. Once granted by the FDA, the Total Risperidone Assay Kit will be
available for sale in the US.

Saladax will be exhibiting at Booth 4135 and will be sponsoring an
Industry Workshop Theater. Dr. Salvatore Salamone (President and CEO of
Saladax Biomedical, Inc.) and Dr. William Clarke (Director of Clinical
Toxicology at Johns Hopkins Medical Institutions) will be presenting
Antipsychotic Therapeutic Drug Management (TDM): A Tool for Adherence
and Dose Optimization
on Wednesday, August 01, 2018: 12:45
PM - 1:45 PM.

Wednesday, August 1,

Analytical Performance of MyCare Psychiatry Assays for
the Detection of Antipsychotic Medications: Risperidone, Clozapine,
Aripiprazole, Olanzapine, Quetiapine and Paliperidone

Session: 9:30 AM - 5:00 PM
Poster Location: B-425 TDM/Toxicology/DAU

About Saladax

Founded in 2004, Saladax
, Inc. is a privately held company headquartered as an
anchor tenant with Ben Franklin TechVentures® located on
Lehigh University's campus in Bethlehem, PA. Saladax develops novel
blood tests that increase the impact of personalized medicine by
bringing chemotherapeutic drug monitoring to oncologists and adherence
testing to psychiatrists. Saladax believes that truly personalized
medicine can only exist when the right drug is given at the right dose.
Our diagnostic reagents and kits are distributed worldwide excluding the
United States. Saladax is ISO 13485:2003 certified.

For more information, visit

View Comments and Join the Discussion!